Welcome to our dedicated page for Endra Life Sciences SEC filings (Ticker: NDRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ENDRA Life Sciences Inc. filings document a Nasdaq-listed medical technology issuer focused on thermoacoustic biomarker imaging and the TAEUS® Liver device for liver fat assessment in steatotic liver disease, MASLD and MASH. Periodic and current reports disclose operating results, clinical-program updates, research and development spending, liquidity, risk factors and common-stock registration matters.
The company’s SEC record also covers material-event reports on private placement financing, at-the-market equity offering arrangements, digital asset treasury disclosures involving HYPE token holdings, supplemental digital-asset risk factors, Nasdaq continued-listing compliance, workforce-related exit costs and strategic-review matters. Proxy materials document director elections, equity incentive plan amendments, auditor matters and other stockholder voting items.
ENDRA Life Sciences Inc. entered into a private placement with an accredited investor, agreeing to sell 578,387 shares of common stock (or prefunded warrants in lieu) plus common warrants to purchase up to 1,156,774 additional shares at an exercise price of $6.57 per share. Each share (or prefunded warrant) and accompanying common warrants were priced at a combined $6.57, for expected gross proceeds of approximately $3.8 million, with Lucid Capital Markets acting as placement agent.
The company granted the investor registration rights and issued prefunded warrants and common warrants that are subject to stockholder approval and beneficial ownership limits, with common warrants exercisable for five years after exercisability begins. A Side Letter requires ENDRA to maintain at least the $3.8 million Purchase Price in a segregated account and potentially repay that amount, net of the fair market value of securities purchased, if it decides not to pursue a specified strategic alternative, and gives the investor a board observer right.
As compensation, the placement agent will receive prefunded warrants for up to 100,000 shares. The company notes that its stockholders’ equity was $2,260,120 as of its most recent Form 10-K, below Nasdaq’s $2.5 million minimum, and that Nasdaq staff has initiated a delisting process subject to a hearing. ENDRA believes that, as a result of this offering, its stockholders’ equity now exceeds $2.5 million and is awaiting formal Nasdaq confirmation.
ENDRA Life Sciences Inc. requested voluntary withdrawal of its Registration Statement on Form S-1 (File No. 333-288575), effective May 26, 2026 or the earliest practicable date. The company states the registration was not declared effective and no securities covered by the Registration Statement have been issued or sold. The company also requested that fees paid under Rule 457(p) be credited to its account for future use.
ENDRA Life Sciences Inc. reported a Q1 2026 net loss of $1,311,433, wider than $1,036,330 a year earlier, as operating expenses rose to $2,173,748 on higher research, general and administrative, and share-based compensation costs.
Cash fell to $356,462 with negative working capital of $298,774, while digital assets increased in value to $2,430,781, generating realized and unrealized gains plus staking income. The company has an accumulated deficit of $111,776,942 and discloses substantial doubt about its ability to continue as a going concern.
Management is pursuing cost reductions, potential equity financing, and strategic alternatives. After quarter-end, Nasdaq notified ENDRA that its stockholders’ equity no longer meets the exchange’s minimum requirement, creating a delisting risk if compliance is not regained.
ENDRA Life Sciences Inc. reported that Nasdaq has again found the company out of compliance with its minimum stockholders’ equity listing standard. Nasdaq requires at least $2,500,000 of stockholders’ equity, while ENDRA reported $2,260,120 in its Form 10-K for the year ended December 31, 2025.
Nasdaq staff has notified ENDRA that its securities are subject to delisting unless it requests a hearing before the Nasdaq Hearings Panel. The company plans to request this hearing, which will temporarily halt delisting actions, and is evaluating options to increase equity and regain compliance, though there is no assurance it will succeed.
ENDRA Life Sciences Inc. files its annual report describing a medical imaging business focused on its Thermo-Acoustic Enhanced Ultrasound (TAEUS) platform for liver fat assessment in metabolic disease. The company is early-stage, with an accumulated deficit of $110.4 million as of December 31, 2025 and an auditor warning of substantial doubt about its ability to continue as a going concern.
Management has halted clinical activities needed for a new FDA De Novo submission for its liver application after cost reductions, cut headcount from 11 to 4 employees, and significantly scaled back commercial operations to conserve cash. In March 2026, the board began evaluating strategic alternatives, including investments, mergers, asset sales or a potential sale or merger of the company, with no outcome guaranteed.
ENDRA also introduces a Digital Asset Treasury strategy, run with Arca Investment Management, to invest excess capital primarily in one to five decentralized finance cryptocurrencies, initially HYPE, held with Anchorage Digital Bank. This financial initiative operates alongside its core TAEUS commercialization plans targeting pharmaceutical trials and metabolic care markets.
ENDRA Life Sciences reported a smaller net loss for 2025 while continuing to invest in its TAEUS thermoacoustic liver imaging platform and reviewing strategic alternatives. The company focuses on steatotic liver disease, aiming to offer a more accessible, ultrasound-based diagnostic option.
Operating expenses for 2025 fell to $5.8 million from $10.8 million in 2024, reflecting streamlining efforts, including a prior non-cash inventory charge. Net loss improved to $7.0 million from $11.5 million, helped by lower research, sales and marketing, and general and administrative costs.
In the fourth quarter of 2025, cash used in operations was $1.6 million. As of December 31, 2025, ENDRA held $762,365 in cash and cash equivalents and $2.0 million in digital assets, forming part of its capital management strategy alongside lease and warrant liabilities.
ENDRA Life Sciences Inc. is launching a formal review of strategic alternatives aimed at maximizing shareholder value while continuing to pursue its TAEUS thermoacoustic imaging business. The Board will consider options such as strategic investments, mergers, business combinations, collaborations, asset sales, or a sale or merger of the Company, with Lucid Capital Management as financial advisor and K&L Gates as legal counsel. In connection with this shift, ENDRA reduced its workforce on March 19, 2026 and expects to record approximately $51,000 in pre-tax severance charges in the first quarter of 2026.
ENDRA Life Sciences reported that Chief Executive Officer Alexander Y. Tokman acquired 26,921 shares of common stock through a grant of restricted stock units (RSUs) at a price of $0.00 per share. These RSUs convert to common stock on a one-for-one basis and will vest in full on June 11, 2026. Following this award, Tokman directly holds 101,926 shares of common stock, and the holdings disclosure notes that this amount includes unvested RSUs.
ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, received a grant of 13,461 shares of common stock as a stock award. The shares, structured as restricted stock units that convert one-for-one into common stock, will vest in full on June 11, 2026. Following this award, Jacroux holds 33,461 shares of common stock, including unvested restricted stock units.
ENDRA Life Sciences Inc. director Anthony DiGiandomenico reported a stock-based award of the company’s common stock. On January 21, 2026, he acquired 60,324 shares at a price of $0, representing restricted stock units (RSUs) that convert to common stock on a one-for-one basis. These RSUs will vest in full on January 21, 2027, meaning he will receive the underlying shares on that date if vesting conditions are met. After this grant, he beneficially owns 136,589 shares of ENDRA common stock, held directly, which includes unvested RSUs.